DDX53 and neoplasm: Second, in a xenograft tumor model, ten days after subcutaneous injection of 3×105 CT26 into the BalB/C mice, 12.5 mg/kg of 13-1-e was intraperitoneally administrated every other day for each mouse (N = 5).